Lumos Pharma, Inc. (LUMO)
NASDAQ: LUMO · IEX Real-Time Price · USD
1.460
+0.010 (0.69%)
At close: Jul 19, 2024, 4:00 PM
1.430
-0.030 (-2.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.
Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.
The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.
Lumos Pharma, Inc. is headquartered in Austin, Texas.
Lumos Pharma, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Richard J. Hawkins |
Contact Details
Address: 4200 Marathon Blvd., Suite 200 Austin, Texas 78756 United States | |
| Phone | 512-215-2630 |
| Website | lumos-pharma.com |
Stock Details
| Ticker Symbol | LUMO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001126234 |
| CUSIP Number | 55028X109 |
| ISIN Number | US55028X1090 |
| Employer ID | 42-1491350 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard J. Hawkins | Founder, Chief Executive Officer and Chairman |
| Dr. John C. McKew Ph.D. | Chief Scientific Officer and President |
| Lori D. Lawley CPA | Chief Financial Officer and Principal Accounting Officer |
| Lisa Miller | Senior Director of Investor Relations |
| Bradley J. Powers J.D. | Chief Compliance Officer and General Counsel |
| Aaron Schuchart B.B.A., CPA, M.B.A. | Chief Business Officer |
| Dr. Pisit Pitukcheewanont FAAP, M.D. | Chief Medical Officer |
| Eddie L. Varnado M.B.A. | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| Apr 22, 2024 | 10-K/A | [Amend] Annual report |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 15, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 10-K | Annual Report |